Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb;49(2):783-7.
doi: 10.1128/AAC.49.2.783-787.2005.

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole

Annemarie Borst  1 , Maria T Raimer, David W Warnock, Christine J Morrison, Beth A Arthington-Skaggs
Affiliations

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole

Annemarie Borst et al. Antimicrob Agents Chemother. 2005 Feb.

Abstract

Five azole-susceptible Candida glabrata isolates obtained before 1975 became resistant to fluconazole, itraconazole, and voriconazole within 4 days of in vitro fluconazole exposure. This cross-resistance was stable for at least 4 months after removal of fluconazole and was associated with increased CgCDR1 and CgCDR2 expression.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
RAPD patterns for C. glabrata isolate 75/015. Lane 1, parental isolate; lane 2, no-fluconazole control isolate at day 136; lane 3, resistant mutant at day 136 (exposed to fluconazole for 14 days and then cultivated in the absence of fluconazole for 122 days). (A) Primer OPE-18; (B) primer OPE-04; (C) primer OPA-01; (D) primer OPA-02; (E) primer OPA-04; (F) primer OPA-10; (G) primer OPA-16; (H) primer OPA-18.
FIG. 2.
FIG. 2.
Quantification of CgERG11, CgCDR1, and CgCDR2 mRNA by Northern hybridization. Lane 1, parent; lane 2, first resistant mutant; lane 3, last isolate collected. MICs are the fluconazole MICs (in micrograms per milliliter).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. - PubMed
    1. Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777. - PMC - PubMed
    1. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539. - PMC - PubMed
    1. Cowen, L. E., D. Sanglard, D. Calabrese, C. Sirjusingh, J. B. Anderson, and L. M. Kohn. 2000. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182:1515-1522. - PMC - PubMed
    1. Defontaine, A., J. P. Bouchara, P. Declerk, C. Planchenault, D. Chabasse, and J. N. Hallet. 1999. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J. Med. Microbiol. 48:663-670. - PubMed

Publication types

MeSH terms